Welcome to our dedicated page for Inspiremd SEC filings (Ticker: NSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading InspireMD’s dense filings can feel like a clinical trial of patience. Hundreds of pages track MicroNet-covered stent efficacy, FDA milestones and global trial costs—details that drive the share price but hide in footnotes.
Our platform turns that complexity into clarity. Whether you need the full InspireMD annual report 10-K simplified or the latest InspireMD quarterly earnings report 10-Q filing, Stock Titan’s AI pinpoints R&D spend, cash runway and pivotal trial updates in seconds. Real-time alerts surface every InspireMD insider trading Form 4 transactions notice, so you never miss executive stock moves.
Here’s what you can uncover today:
- Form 4 dashboards for InspireMD executive stock transactions Form 4 with real-time push.
- Instant summaries that answer “What changed in this 10-Q?” for busy clinicians and fund managers.
- 8-K trackers that flag device-approval news—InspireMD 8-K material events explained.
- Proxy insights that decode InspireMD proxy statement executive compensation versus peer med-tech firms.
No more line-by-line reading to find trial enrollment numbers or manufacturing cost shifts. Our expert layer explains ratios, spotlights risk wording and links related exhibits, making understanding InspireMD SEC documents with AI straightforward.
Save hours, spot inflection points earlier and answer questions like “Is management buying shares?” or “How much was spent on CGuard’s FDA study?” with confidence. Every filing, from the smallest 3-page 8-K to the exhaustive 300-page 10-K, is updated the moment it hits EDGAR—so your analysis stays ahead of the next catheter deployment.
InspireMD, Inc. (NSPR) has filed a Form 8-K dated July 9, 2025 to furnish a Regulation FD disclosure.
Under Item 7.01, the company states that it has issued a press release entitled “InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke.” The full press release is included as Exhibit 99.1, but its text is not reproduced in the filing. Management emphasizes that the information is being furnished, not filed, meaning it is excluded from Exchange Act Section 18 liability and will not be incorporated into other SEC filings unless specifically referenced.
The filing contains no financial statements, guidance, or transaction details. The exhibit list consists of:
- 99.1 – Press Release (July 9, 2025)
- 104 – Cover Page Interactive Data File
Beyond the announcement of the U.S. commercial launch of CGuard Prime—InspireMD’s carotid stent designed to reduce stroke risk—no additional quantitative or strategic information is provided.
InspireMD's new Chief Financial Officer Michael Lawless filed an initial Form 3 statement disclosing his beneficial ownership position upon appointment. The filing reveals two key components of his compensation package:
- 465,000 restricted stock shares vesting in three equal annual installments of 155,000 shares each on June 25, 2026, 2027, and 2028
- 212,000 stock options with an exercise price of $2.24, vesting similarly in three equal annual installments through 2028
All equity awards are contingent on Lawless's continued service with the company. This initial beneficial ownership disclosure, filed within the required timeline following his appointment, demonstrates a significant equity-based compensation structure aligned with long-term shareholder interests through the extended vesting schedule.
InspireMD has received FDA Premarket Approval (PMA) for its CGuard Prime Carotid Stent System on June 23, 2025, marking a significant regulatory milestone. This approval follows their PMA application submitted on September 16, 2024.
Key developments include:
- FDA PMA approval for stroke prevention device
- Release of updated investor presentation available on company website
- Trading on Nasdaq Capital Market under symbol NSPR
The company issued a press release on June 24, 2025, announcing the approval. The filing includes two key exhibits: the press release and an updated investor presentation. This regulatory achievement potentially opens up the U.S. market for InspireMD's carotid stent system, representing a material development for the company's commercial prospects.
FAQ
What is the current stock price of Inspiremd (NSPR)?
What is the market cap of Inspiremd (NSPR)?
